In addition, Äyräväinen et al. [23] reported no effect on periodontal parameters in 26 RA patients starting treatment with biological DMARDs (mainly anti-TNF therapy; adalimumab, etanercept, golimumab and certolizumab pegol) after a median of 16 months. This evidence concerns the gene TNF and rheumatoid arthritis.